Application Areas
GEG Tech’s RNA-BEV platform for programmable antigen delivery
RNA-ONE is GEG Tech’s proprietary RNA-BEV technology for transient delivery of functional RNA in vivo.
For vaccination, the platform provides several complementary capabilities:
Programmable antigen cargo
RNA-ONE can encode different antigenic proteins without changing the underlying delivery principle.
Combination strategies
RNA cargos can be designed to combine antigen expression with additional biological signals intended to shape or reinforce the immune response.
Multiple administration strategies
RNA-ONE has been evaluated through different routes of administration, enabling vaccine programs to be adapted to the biology of the pathogen and the immune response sought.
Engineerable particle biology
The RNA-ONE envelope can be modified, providing a route to adapt cellular interactions and tropism as vaccine programs evolve.
Together, these properties make RNA-ONE a platform for programmable RNA vaccination rather than a vector dedicated to a single antigen.
RNA-ONE has been evaluated in several preclinical vaccination programs targeting pathogens for which satisfactory vaccines remain unavailable or insufficient.
These programs include distinct pathogen biology, antigen designs and vaccination strategies.
RNA-ONE has generated positive preclinical results in mouse vaccination studies, supporting the ability of the platform to induce biologically relevant immunity against a complex parasitic pathogen.
Different doses and administration routes have been evaluated, providing a foundation for further translational development.
RNA-ONE has also been evaluated in preclinical models of leishmaniasis.
The program explores not only antigen delivery, but also the possibility of combining RNA-encoded biological functions to modulate the quality of the immune response.
This illustrates an important capability of RNA vaccination:
the cargo can program both what the immune system sees and how the biological response is shaped.
RNA-ONE is also being explored in additional vaccine programs, including bacterial pathogens, to test different antigen combinations, administration routes and immunization strategies.
Together, these programs demonstrate the versatility of the platform across very different infectious-disease contexts.
One of the main advantages of an RNA platform is that changing the vaccine target does not necessarily require rebuilding the delivery technology.
The biological instruction can change while the vector platform remains.
RNA-ONE can therefore support:
single-antigen strategies,
and potentially antigen + immunomodulator combinations.
This creates a modular development logic particularly suited to pathogens where antigen selection and immune-response quality remain major challenges.
RNA-ONE is already an in vivo delivery platform.
Its development does not depend on removing or manipulating cells outside the body.
The vaccine cargo is delivered directly, expressed transiently and then naturally declines.
This is particularly relevant to vaccination, where the objective is not persistent expression of the vaccine antigen but the establishment of durable immune memory following temporary biological exposure.
RNA-ONE therefore separates:
from
the duration of immune protection.
A successful vaccine platform must ultimately address more than immunogenicity.
Manufacturing, stability, administration and distribution all influence industrial feasibility.
RNA-ONE is based on a common biologically assembled platform that can accommodate different RNA cargos while preserving the core production architecture.
The platform has also demonstrated room-temperature stability in preclinical studies, an attribute of potential relevance to vaccine storage and distribution.
Combined with its modular RNA cargo and ability to support different administration strategies, this provides a practical foundation for partner-driven vaccine development.
RNA-ONE has moved beyond the stage of exploratory RNA vaccination.
The platform has already been:
evaluated in multiple infectious-disease programs,
tested with different RNA cargos,
administered through different vaccination routes,
and associated with positive preclinical immune and protection-related outcomes.
GEG Tech can therefore engage RNA-ONE directly in partner-driven vaccine programs.
Development can begin from an existing antigen, antigen combination or vaccine concept and focus on integrating the biological instruction into the RNA-ONE platform and defining the appropriate administration and immunization strategy.
The objective is to allow industrial partners to build on an existing RNA-delivery platform and preclinical knowledge base, rather than developing a new delivery system for every pathogen.
| Development milestone | Status |
|---|---|
| RNA vaccine delivery platform | Established |
| Antigen expression in vitro | Demonstrated |
| In vivo RNA delivery | Demonstrated |
| Immunogenicity in preclinical models | Demonstrated |
| Multiple pathogen programs | Demonstrated |
| Multiple administration routes | Evaluated |
| Antigen + immunomodulation strategies | Demonstrated / under development |
| Room-temperature stability | Demonstrated preclinically |
| Protection-related efficacy in disease models | Demonstrated in selected programs |
| Partner-specific vaccine development | Available |
GEG Tech operates through a collaborative studio-lab model.
RNA-ONE vaccine programs can be developed around an industrial or academic partner’s antigen portfolio and translational strategy.
Collaboration can include:
Integration of selected antigens or antigen combinations into RNA-ONE.
Combination of antigen expression with additional biological signals where relevant.
Adaptation of the RNA-ONE architecture and, where appropriate, envelope properties.
Evaluation of dose, route and immunization schedule.
Assessment of immunogenicity, protection, biodistribution and biological response.
Progression toward pathogen-specific industrial development programs.
Bring the antigen. We engineer the RNA vaccination strategy around the immune objective.
RNA-ONE development in vaccination has progressed across multiple pathogen programs, from antigen vectorization to in vivo immunogenicity and preclinical efficacy.
Preclinical milestone
RNA-ONE has generated positive preclinical results in vaccination programs targeting pathogens for which satisfactory vaccines remain unavailable or insufficient.
Platform milestone
RNA-ONE supports the development of vaccine strategies combining transient antigen expression with additional RNA-encoded biological functions.